Table 2.
Basic characteristics of the inclusion study
| Study | Male | Female | Open biopsy | Partial resection | Complete resection | Experimental/control |
| Chinot et al10 | 282 (61.6)/ 298 (64.4) |
176 (38.4)/ 165 (35.6) |
60 (13.1)/ 44 (9.5) |
210 (45.9)/ 223 (48.2) |
188 (41.0)/ 196 (42.3) |
BEV+RT–TMZ/ Placebo+RT–TMZ |
| Qianru11 | 14/12 | 11/12 | / | 15/16 | 10/8 | BEV+TMZ/TMZ |
| Herrlinger et al12 | 80 (69.0)/ 34 (63.0) |
36 (31.0)/ 20 (37.0) |
0/2 (;3.7) | 58 (;50.0)/ 27 (;50.0) |
58 (50.0)/ 25 (46.3) |
BEV+IRI/TMZ |
| Gilbert et al13 | / | / | / | / | / | Bevacizumab/placebo |
| Chen et al14 | 30 (;53)/ 45 (;57)/ 15 (;65) |
57/79/23 27 (;47)/ 34 (;43)/ 8 (;35) |
34 (;60)/ 44 (;56)/ 14 (;61) |
20 (;35)/ 33 (;42)/ 9 (;39) |
3 (;5)/ 2 (;2)/ 0 (;0) |
Bevacizumab monotherapy /bevacizumab combination /non-bevacizumab |
| Hualong et al15 | 19/18 | 12/13 | / | / | / | TMZ+BEV/TMZ |
| Zhixian et al16 | 22 | 18 | / | 18 | 22 | BEV+TMZ/Gamma knife+TMZ |
| Jiaqi et al17 | 16/14 | 11/13 | / | / | / | TMZ+BEV/TMZ |
| Albert et al18 | 31/40 | 39/70 | 2/23 | 40/40 | 28/47 | RT+TMZ+BV/RT/TMZ |
| Chauffert et al19 | 26/23 | 34/37 | / | / | / | BEV+IRI/TMZ+RT |
| Balana et al20 | 31/25 | 17/20 | 42/35 | / | / | TMZ+BEV/TMZ |
BEV, bevacizumab; BV, Bevacizumab; IRI, Irinotecan; RT, radiotherapy; TMZ, temozolomide.